Long‐term functional stability of problem behavior exposed to psychotropic medications

Cox et al. (2022) watched problem behavior while doctors changed antipsychotic doses. They ran a continuous functional analysis before, during, and after each change.

The team worked with people who had intellectual or developmental disabilities. They wanted to know if the behavior’s function shifted when the drug dose went up or down.

Across 14 different dose tweaks, behavior barely budged. The function stayed the same even when the dose changed.

Small drops in problem behavior showed up, but they were tiny. The data say the medicine edits did not rewrite why the behavior happened.

Northup et al. (1991) also used functional analysis with people with ID. They saw big, quick drops in aggression when the reinforcer was switched to a new response. Cox sees almost zero change when only the pill changes, showing contingencies trump dose tweaks.

Matson et al. (1999) reviewed piles of studies and found that after an FA, teams pick reinforcement plans, not more drugs. Cox’s data back that up: if the function holds steady, behavior-based treatment stays the right call.

Hutchins et al. (2020) saw antipsychotics hurt gait in adults with ID. Cox shows the same drugs barely touch behavior. Together, the papers hint the meds give little gain and some motor cost.

You can stop waiting for the next med change to fix problem behavior. Run your FA, see the function, and build a behavior plan right away. Keep the analysis in place after each dose tweak so you catch any real shift early and avoid months of useless tinkering.